Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1;28(5):860-869.
doi: 10.1158/1078-0432.CCR-21-1090.

The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Jimmy L Zhao  1   2 , Karim Fizazi  3 , Fred Saad  4 , Kim N Chi  5 , Mary-Ellen Taplin  6 , Cora N Sternberg  7 , Andrew J Armstrong  8 , Johann S de Bono  9 , William T Duggan  10 , Howard I Scher  1   11
Affiliations

The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Jimmy L Zhao et al. Clin Cancer Res. .

Abstract

Purpose: The clinical impact of concurrent corticosteroid use (CCU) on enzalutamide-treated patients with metastatic castration-resistant prostate cancer (mCRPC) is unknown. We investigated the association of CCU with overall survival (OS), radiographic progression-free survival (rPFS), and time to prostate-specific antigen progression (TTPP) in post-chemotherapy, enzalutamide-treated patients with mCRPC.

Patients and methods: Post hoc analysis of AFFIRM (NCT00974311) with patients (n = 1,199) randomized 2:1 to enzalutamide 160 mg/day or placebo. Treatment group, CCU, and known prognostic factors were evaluated for impact on OS, rPFS, and TTPP using a multivariate Cox proportional hazards model. CCU was defined as "baseline" (use started at baseline) or "on-study" (baseline plus use that was started during the trial).

Results: Enzalutamide significantly improved OS, rPFS, and TTPP independent of baseline CCU but was associated with inferior clinical outcomes when compared with no baseline CCU, including a shorter OS [10.8 months vs. not reached (NR); HR for use vs. no use, 2.13; 95% confidence interval (CI), 1.79-2.54], rPFS (5.2 months vs. 8.0 months; HR, 1.49; 95% CI, 1.29-1.72], and TTPP (4.6 months vs. 5.7 months; HR, 1.50; 95% CI, 1.25-1.81). These findings held in a multivariate analysis adjusting for baseline prognostic factors wherein baseline CCU was independently associated with decreased OS (HR, 1.71; 95% CI, 1.43-2.04; P < 0.0001) and rPFS (HR, 1.28; 95% CI, 1.11-1.48; P = 0.0007).

Conclusions: Patients with mCRPC benefited from enzalutamide treatment independent of CCU, but CCU was associated with worse baseline prognostic factors and outcomes.

PubMed Disclaimer

Figures

Figure 1. OS (A), rPFS (B), and PSA PFS (C), with and without baseline corticosteroid use. NR, not reached.
Figure 1.
OS (A), rPFS (B), and PSA PFS (C), with and without baseline corticosteroid use. NR, not reached.
Figure 2. Assessment of treatment-by-baseline corticosteroid use interaction analysis (A) and effects of baseline corticosteroid use on OS, rPFS, and TTPP in patients stratified into high-risk or low-risk groups (B).
Figure 2.
Assessment of treatment-by-baseline corticosteroid use interaction analysis (A) and effects of baseline corticosteroid use on OS, rPFS, and TTPP in patients stratified into high-risk or low-risk groups (B).
See this image and copyright information in PMC

References

    1. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253–61. - PubMed
    1. Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol 2019;9:801. - PMC - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005. - PMC - PubMed
    1. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–48. - PMC - PubMed
    1. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–97. - PubMed

Publication types

Associated data

LinkOut - more resources